Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.59 |
| ▸ | DRD4 | P21917 | 3/20 | 0.59 |
| ▸ | DRD3 | P35462 | 3/20 | 0.59 |
| ▸ | GCK | P35557 | 7/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26686598 | 0.86 | GCK (0.50) | DRD2DRD4DRD3GCK | |
| SCHEMBL26686140 | 0.76 | DAO (0.39) | DRD2DRD4DRD3GCK | |
| SCHEMBL26686565 | 0.75 | GCK (0.43) | DRD2DRD4DRD3GCK | |
| SCHEMBL29460523 | 0.74 | RIPK1 (0.60) | DRD2DRD4DRD3 | |
| SCHEMBL7411386 | 0.74 | DRD2 (0.49) | DRD2DRD4DRD3 | |
| SCHEMBL6025264 | 0.73 | DRD2 (0.51) | DRD2DRD4DRD3 | |
| SCHEMBL28256598 | 0.73 | NR3C1 (0.48) | DRD2DRD4DRD3 | |
| SCHEMBL26686439 | 0.72 | DRD2 (0.47) | DRD2DRD4DRD3GCK | |
| SCHEMBL7407178 | 0.72 | DRD2 (0.47) | DRD2DRD4DRD3 | |
| SCHEMBL3492565 | 0.72 | DRD2 (0.58) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | DRD2 4529/4885DRD4 4250/4885DRD3 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.